

## P.ENT COOPERATION TREA.

From the INTERNATIONAL BUREAU

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

Date of mailing (day/month/year) 01 December 2000 (01.12.00)	To:  Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/AU00/00389	Applicant's or agent's file reference P17237PC00
International filing date (day/month/year) 01 May 2000 (01.05.00)	Priority date (day/month/year) 29 April 1999 (29.04.99)
Applicant FUCHSHUBER, Lilian et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

16 November 2000 (16.11.00)

in a notice effecting later election filed with the International Bureau on:

\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Claudio Borton
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of Receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) P17237PC00

### Box No. I TITLE OF INVENTION

NON-AQUEOUS LIQUID SHAMPOO COMPOSITION

### Box No. II APPLICANT

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Soltec Research Pty Ltd.,  
8 Macro Court,  
Rowville, Victoria 3178  
Australia.

This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (i.e. country) of nationality:  
Australia

State (i.e. country) of residence:  
Australia

This person is applicant  all designated  all designated States except States the United States of America  the United States of America only  The States indicated in the Supplemental Box

### Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Fuchshuber, Lilian,  
38 Tinks Road,  
Narre Warren, Victoria 3805  
Australia

This person is:

applicant only

applicant and inventor

inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:  
Australia

State (i.e. country) of residence:  
Australia

This person is applicant  all designated  all designated States except States the United States of America  the United States of America only  The States indicated in the Supplemental Box

Further applicants and/or (further) inventors are indicated on a continuation sheet

### Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:  agent  common representative

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Telephone No.  
(03) 9819 1664

WATERMARK PATENT & TRADEMARK ATTORNEYS  
290 Burwood Road,  
Hawthorn, Victoria 3122  
Australia

Facsimile No.  
(03) 9819 6010

Teleprinter No.

Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet is not to be included in the request

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Harding, Ron  
128 Research Road,  
North Warrandyte, Victoria 3113,  
Australia

This person is:

- applicant only
- applicant and inventor
- inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:  
AustraliaState (i.e. country) of residence:  
AustraliaThis person is applicant for the purposes of:  all designated States     all designated States except the United States of America     the United States of America only     the States indicated in the Supplemental Box

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

This person is:

- applicant only
- applicant and inventor
- inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:  all designated States     all designated States except the United States of America     the United States of America only     the States indicated in the Supplemental Box

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

This person is:

- applicant only
- applicant and inventor
- inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:  all designated States     all designated States except the United States of America     the United States of America only     the States indicated in the Supplemental Box

Name and Address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

This person is:

- applicant only
- applicant and inventor
- inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:  all designated States     all designated States except the United States of America     the United States of America only     the States indicated in the Supplemental Box Further applicants and/or (further inventors are indicated on a continuation sheet.

See Notes to the request form

**Box No. V DESIGNATION OF STATE**

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

AP ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a contracting State of the Harare Protocol and of the PCT

EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, any other State which is a Contracting State of the European Patent Convention and of the PCT

OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (*if other kind of protection or treatment desired, specify on dotted line*)

**National Patent (if other kind of protection or treatment desired, specify on dotted line):**

AE United Arab Emirates.....  
 AL Albania.....  
 AM Armenia .....

AT Austria.....  
 AU Australia.....  
 AZ Azerbaijan .....

BA Bosnia and Herzegovina .....

BB Barbados .....

BG Bulgaria.....  
 BR Brazil.....  
 BY Belarus .....

CA Canada .....

CH and LI Switzerland and Liechtenstein .....

CN China.....  
 CU Cuba.....  
 CZ Czech Republic .....

DE Germany.....  
 DK Denmark.....  
 EE Estonia .....

ES Spain.....  
 FI Finland .....

GB United Kingdom.....  
 GD Grenada .....

GE Georgia .....

GH Ghana.....  
 GM Gambia.....  
 HR Croatia .....

HU Hungary .....

ID Indonesia .....

IL Israel .....

IN India .....

IS Iceland .....

JP Japan .....

KE Kenya .....

KG Kyrgyzstan .....

KP Democratic People's Republic of Korea .....

KR Republic of Korea .....

KZ Kazakstan.....  
 LC Saint Lucia .....

LK Sri Lanka .....

LR Liberia .....

LS Lesotho .....

LT Lithuania .....

LU Luxembourg .....

LV Latvia .....

MD Republic of Moldova .....

MG Madagascar .....

MK The Former Yugoslav Republic of Macedonia .....

MN Mongolia .....

MW Malawi .....

MX Mexico .....

NO Norway .....

NZ New Zealand .....

PL Poland .....

PT Portugal .....

RO Romania .....

RU Russian Federation .....

SU Sudan .....

SE Sweden .....

SG Singapore .....

SI Slovenia .....

SK Slovakia .....

SL Sierra Leone .....

TJ Tajikistan .....

TM Turkmenistan .....

TR Turkey .....

TT Trinidad and Tobago .....

UA Ukraine .....

UG Uganda .....

US United States of America .....

UZ Uzbekistan .....

VN Viet Nam .....

YU Yugoslavia .....

ZA South Africa' .....

ZW Zimbabwe .....

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

CR Costa Rica .....

DM Dominica .....

MA Morocco .....

AG Antigua & Barbados .....

DZ Algeria .....

MZ Mozambique .....

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except the designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

See notes to the request form

**Box No. VI PRIORITY CLAIM** Further priority claims are indicated in the Supplemental Box

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is : -		
		national application: country	regional application: regional Office	international application: receiving Office
item (1) (29.04.1999) 29th April, 1999	PQ0029	Australia		Australia
item (2)				
item (3)				

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office for the purposes of the present international application is the receiving Office) identified above as item(s). item 1

Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii). See Supplemental Box.

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA)  
(If two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen, the two-letter code may be used):

Request to use results of earlier search; reference to that search (if earlier search has been carried out by or requested from the International Searching Authority):

Date (date/month/year)      Number      Country (or regional Office)

ISA /

**Box No. VIII CHECK LIST; LANGUAGE OF FILING**

The international application contains the following number of sheets:

request : 4  
description excluding sequence listing part : 19  
claims : 2  
abstract : 1  
drawings :  
sequence listing part of description :  
Total number of sheets : 26

This international application is accompanied by the item(s) marked below:

1.  fee calculation sheet
2.  separate signed power of attorney
3.  copy of general power of attorney; reference number, if any:
4.  statement explaining lack of signature
5.  priority document(s) identified in Box No. VI as item(s):
6.  translation of international application into (language):
7.  separate indications concerning deposited microorganisms or other biological material
8.  nucleotide and/or amino acid sequence listing in computer readable form
9.  other (specify):

Figure of the drawings which should accompany the abstract:

Language of filing of the international application: ENGLISH

**Box No. IX SIGNATURE OF APPLICANT OR AGENT**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

  
Karen J Sinclair, Registered Patent Attorney  
for and on behalf of WATERMARK PATENT & TRADEMARK ATTORNEYS

		For receiving Office use only		2. Drawings:  <input type="checkbox"/> received:  <input type="checkbox"/> not received:
		1. Date of actual receipt of the purported international application:	3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):		5. International Searching Authority (if two or more are competent): ISA /		6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid

For International Bureau use only		
Date of receipt of the record copy by the International Bureau:		

# PATENT COOPERATION TREATY

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:  
WATERMARK PATENT & TRADEMARK  
ATTORNEYS  
Locked Bag 5  
HAWTHORN VIC 3122

**PCT**

WRITTEN OPINION

(PCT Rule 66)

		Date of mailing (day/month/year)	<b>29 DEC 2000</b>
Applicant's or agent's file reference <b>P17237PC</b>		REPLY DUE	within <b>TWO MONTHS</b> from the above date of mailing
International application No. <b>PCT/AU 00/00389</b>	International filing date (day/month/year) <b>01 May 2000</b>	Priority Date (day/month/year) <b>29 April 1999</b>	
International Patent Classification (IPC) or both national classification and IPC <b>Int. Cl. 7 A61K 47/44 A61P 17/06, 17/14, 17/04</b>			
Applicant			
1. SOLTEC RESEARCH PTY. LTD. et al			

1. This written opinion is the **FIRST** drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I       Basis of the opinion
- II      Priority
- III     Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV     Lack of unity of invention
- V      Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI     Certain documents cited
- VII    Certain defects in the international application
- VIII    Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also** For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4bis. For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **29 August 2001**

Name and mailing address of the IPEA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA E-mail address: <a href="mailto:pct@ipaaustralia.gov.au">pct@ipaaustralia.gov.au</a> Facsimile No. (02) 6285 3929	Authorized Officer  JENNIFER FERNANCE Telephone No. (02) 6283 2416
---	---

**I. Basis of the opinion****1. With regard to the elements of the international application.\***

the international application as originally filed.

the description,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of .

the claims,      pages , as originally filed,  
                              pages , as amended under Article 19,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of .

the drawings,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of .

the sequence listing part of the description:  
                              pages , as originally filed  
                              pages , filed with the demand  
                              pages , received on    with the letter of .

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).  
 the language of publication of the international application (under Rule 48.3(b)).  
 the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:**

contained in the international application in printed form.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority in written form.  
 furnished subsequently to this Authority in computer readable form.  
 The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4.  The amendments have resulted in the cancellation of:**

the description,      pages  
 the claims,          Nos.  
 the drawings,        sheets/fig

**5.  This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims - Claims 1-11	YES NO
Inventive step (IS)	Claims - Claims 1-11	YES NO
Industrial applicability (IA)	Claims 1-9, 11 Claims 10	YES NO

**2. Citations and explanations**

Documents are cited in order in order of their appearance in the ISR

Novelty (N) Claims 1-11

D7 (Remington's) is cited as an example of common general knowledge of the art of cosmetics and pharmaceutical formulation chemistry.

D1 discloses cosmetic and pharmaceutical compositions as claimed in claims 1-8, 10, and 11. D2, D3 and D5 disclose cosmetic and pharmaceutical compositions as claimed in claims 1, 4-8, 10 and 11. D4 discloses cosmetic and pharmaceutical compositions as claimed in claims 1, 2, 4, 7-8, 10 and 11. In light of comments made in Box VIII, D6 discloses claims 1-11.

The invention as claimed in claims 1-11 resides in the use of known cosmetic and pharmaceutical bulking/dispersing/solvents/thickening excipients such as PEG, hydroxy propyl cellulose and PPG. The use of such agents in substantially non-aqueous compositions is known (for example, see Remington's). The variation of concentration of these agents in order to obtain degrees of viscosity is also well known to the skilled addressee (a formulation chemist) as would the selection of a well known excipient in order not to effect the detergent and/or pharmaceutical active. Thus the choice of bulking/dispersing/thickening excipient and its concentration does not confer novelty on these claims.

None of the cited documents disclose the composition of claim 9.

Inventive Step (IS) Claims 1-11

In light of comments made above, the person skilled in the art ~~person skilled in the art~~ with the same problem to be solved and in light of the given documents, alone or in combination, and the common general knowledge of formulation chemistry, would be led to investigate the invention as presently claimed. The compounds of claim 9 are known pharmaceutical only slightly soluble in water.

Industrial Applicability Claim 10

Rule 67 lists the subject matter which under Article 34(4)(a)(i) an international preliminary examination is not required to be carried out. At item (iv) it specifies methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods, as such matter. However the agreement between WIPO and Australia further qualifies this by excepting from exclusion any subject matter which is examined under national grant procedures. Claims 10 have nonetheless been considered because the identified subject matter does not contravene Australian law.

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The use of the term "detergent" within the claim includes compounds such as surfactants (also used as stabilisers). It also includes the use of water, perfume, ethanol etc. as all these compounds are detergents (cleaning agents)

The bulking agent can also have other activities, for example, glycerol and PEG.

Claim 11 as drafted is considered a process claim.

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

**PCT**

To: Agent :

WATERMARK PATENT & TRADEMARK  
ATTORNEYS  
Locked Bag 5  
HAWTHORN VIC 3122

## NOTIFICATION OF RECEIPT OF DEMAND BY COMPETENT INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

(PCT Rule 59.3(e) and 61.1(b), first sentence  
and Administrative Instructions, Section 601(a))

Date of mailing (day/month/year)	22 NOV 2000 (22/11/00)
-------------------------------------	---------------------------

Applicant's or agent's file reference  
P17237PC

### IMPORTANT NOTIFICATION

International application No. PCT/AU00/00389	International filing date (day/month/year) 1 MAY 2000 (1/5/00)	Priority date (day/month/year) 29 APR 1999 (29/4/99)
---	---	---

Applicant

Soltec Research Pty. Ltd. (et al.)

- The applicant is hereby **notified** that this International Preliminary Examining Authority considers the following date as the date of receipt of the demand for international preliminary examination of the international application:

16 NOV 2000 (16/11/00)

- That date of receipt is:

- the actual date of receipt of the demand by this Authority (Rule 61.1(b)).
- the actual date of receipt of the demand on behalf of this Authority (Rule 59.3(e)).
- the date on which this Authority has, in response to the Invitation to correct defects in the demand (Form PCT/IPEA/404), received the required corrections.

- Attention:** That date of receipt is **AFTER** the expiration of 19 months from the priority date. Consequently, the election(s) made in the demand does (do) not have the effect of postponing the entry into the national phase until 30 months from the priority date (or later in some Offices) (Article 39(1)). Therefore, the acts for entry into the national phase must be performed within 20 months from the priority date (or later in some Offices) (Article 22). For details, see the *PCT Applicant's Guide, Volume II*.

- (*If applicable*) This notification confirms the information given by telephone, facsimile transmission or in person on:

---

- Only where paragraph 3 applies, a copy of this notification has been sent to the International Bureau.

Name and mailing address of the IPEA/AU  
**AUSTRALIAN PATENT OFFICE**  
**PO BOX 200, WODEN ACT 2606, AUSTRALIA**  
E-mail: pct@ipaaustralia.gov.au  
Facsimile No. 02 6283 3929

Authorized officer **JOSEPH BRESIC**  
**02 6283 2357**

Telephone No.

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The name or two-letter code of that Authority may be indicated in the space below:  
IPEA

# P C T

## D E M A N D

## CHAPTER II

under Article 31 of the Patent Cooperation Treaty:

The undersigned requests that the international application specified below be the subject of International preliminary examination according to the Patent Cooperation Treaty.

For International Preliminary Examining Authority use only

Identification of IPEA		Date of Receipt of DEMAND
<b>Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION</b>		Applicant's or agent's file reference
International application No.  PCT/AU00/00389	International filing date (day/month/year)  ((01.05.2000) 1ST May, 2000	(Earliest) Priority date (day/month/year)  (29.04.1999) 29th April, 1999
Title of Invention Non-Aqueous Liquid Shampoo Composition		
<b>Box No. II APPLICANT(S)</b>		
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country).  Soltec Research Pty Ltd., 8 Macro Court, Rowville, Victoria 3178 Australia		Telephone No.:
		Facsimile No.:
		Teleprinter No.:
State (i.e. country) of nationality:  Australia	State (i.e. country) of residence:  Australia	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country).  Fuchshuber, Lilian 38 Tinks Road, Narre Warren, Victoria 3805 Australia.		
State (i.e. country) of nationality:  Australia	State (i.e. country) of residence:  Australia	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country).  Harding, Ron, 128 Research Road, North Warrandyte, Victoria 3113. Australia.		
State (i.e. country) of nationality:  Australia	State (i.e. country) of residence:  Australia	
<input type="checkbox"/> Further applicants are indicated on a continuation sheet.		

**Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The following person is  agent  common representative

and  has been appointed earlier and represents the applicant(s) also for international preliminary examination.

is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.

is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: (*Family name followed by given name; for a legal entity, full official designation.  
The address must include postal code and name of country.*)

Watermark Patent & Trademark Attorneys  
290 Burwood Road,  
Hawthorn, Victoria 3122  
Australia

Telephone No.:

(613) 9819 1664

Faxsimile No.:

(613) 9819 6010

Teleprinter No.:

AA 31762

Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

**Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION****Statement concerning amendments: \***

1. This applicant wishes the International Preliminary Examining Authority to start on the basis of:

the international preliminary examination as originally filed.

the description  as originally filed

as amended under Article 34)

the claims  as originally filed

as amended under Article 19 (together with any accompanying statement)

as amended under Article 34

the drawings  as originally filed

as amended under Article 34

2.  The applicant wishes any amendments to the claims under Article 19 to be considered as reversed.

3.  The applicant wishes any amendments to the claims under Article 19 to be considered to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired).

\* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

**Language for the purposes of international preliminary examination: ENGLISH**

which is the language in which the international application was filed

which is the language of a translation furnished for the purposes of international search.

which is the language of publication of the international application.

which is the language of the translation (to be furnished for the purposes of international preliminary examination).

**Box No. V ELECTION OF STATES**

The applicant hereby elects all eligible States (*that is, all States which have been designated and which are bound by Chapter II of the PCT*)

excluding the following States which the applicant wishes not to elect:

**Box No. VI CHECK LIST**

The demand is accompanied by the following elements, in the language referred to in Box IV, for the purposes of international preliminary examination:

			For International Preliminary Examining Authority use only	
			received	not received
1. translation of international application	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>
2. amendment under Article 34	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>
3. copy (or, where required, translation) of amendments under Article 19	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>
4. copy (or, where required, translation) of statement under Article 19	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>
5. letter	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>
6. other (specify)	:	sheets	<input type="checkbox"/>	<input type="checkbox"/>

This demand is also accompanied by the item(s) marked below:

1. <input checked="" type="checkbox"/> fee calculation sheet	3. <input type="checkbox"/> statement explaining lack of signature
2. <input type="checkbox"/> separate signed power of attorney	4. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable
3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:	5. <input type="checkbox"/> other (specify)

**Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE**

*Next to each signature, indicate the nature of the person signing the capacity in which the person signs (if such capacity is not obvious from reading the demand).*

Amanda L Jones, Registered Patent Attorney  
For and on behalf of Watermark Patent and Trade Mark Attorneys

**For International Preliminary Examining Authority use only**

1. Date of actual receipt of DEMAND:
2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):
3. <input type="checkbox"/> The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply <input type="checkbox"/> The applicant has been informed accordingly.
4. <input type="checkbox"/> The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5
5. <input type="checkbox"/> Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXECUTED pursuant to Rule 82

**For International Bureau use only**

Demand received from IPEA on:

**PATENT COOPERATION TREATY**

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:		<b>PCT</b> NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT  (PCT Rule 71.1)	
WATERMARK PATENT & TRADEMARK ATTORNEYS Locked Bag 5 HAWTHORN VIC 3122		Date of mailing day/month/year	04 JUN 2001
Applicant's or agent's file reference P17237PC00		<b>IMPORTANT NOTIFICATION</b>	
International Application No. <b>PCT/AU00/00389</b>	International Filing Date <b>1 May 2000</b>	Priority Date <b>29 April 1999</b>	
Applicant <b>SOLTEC RESEARCH PTY. LTD. et al</b>			

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

**4. REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide

Name and mailing address of the IPEA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer  <b>JENNIFER FERNANCE</b> Telephone No. (02) 6283 2416
---	--

**ATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>P17237PC00</b>	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International Application No. <b>PCT/AU00/00389</b>	International Filing Date ( <i>day/month/year</i> ) <b>1 May 2000</b>	Priority Date ( <i>day/month/year</i> ) <b>29 April 1999</b>	
International Patent Classification (IPC) or national classification and IPC <b>Int. Cl. 7 A61K 47/44 A61P 17/04, 17/06, 17/14</b>			
Applicant <b>SOLTEC RESEARCH PTY. LTD. et al</b>			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheet(s).

3. This report contains indications relating to the following items:

- I       Basis of the report
- II      Priority
- III     Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV     Lack of unity of invention
- V      Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI     Certain documents cited
- VII    Certain defects in the international application
- VIII    Certain observations on the international application

Date of submission of the demand <b>16 November 2000</b>	Date of completion of the report <b>16 May 2001</b>
Name and mailing address of the IPEA/AU <b>AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929</b>	Authorized Officer  <b>JENNIFER FERNANCE</b> Telephone No. (02) 6283 2416

**I. Basis of the report****1. With regard to the elements of the international application:\***

the international application as originally filed.

the description,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of

the claims,      pages , as originally filed,  
                              pages , as amended (together with any statement) under Article 19,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of

the drawings,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on    with the letter of

the sequence listing part of the description:  
                              pages , as originally filed  
                              pages , filed with the demand  
                              pages , received on    with the letter of

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).  
 the language of publication of the international application (under Rule 48.3(b)).  
 the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:**

contained in the international application in written form.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority in written form.  
 furnished subsequently to this Authority in computer readable form.  
 The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
 The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

**4.  The amendments have resulted in the cancellation of:**

the description,      pages  
 the claims,          Nos.  
 the drawings,        sheets/fig.

**5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be nonobvious), or to be industrially applicable have not been examined in respect of:

the entire international application,  
 claims Nos:

because:

the said international application, or the said claims No. 10 relates to the following subject matter which does not require an international preliminary examination (*specify*):

Rule 67 lists the subject matter which under Article 34(4)(a)(i) an international preliminary examination is not required to be carried out. At item (iv) it specifies methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods, as such matter. However the agreement between WIPO and Australia further qualifies this by excepting from exclusion any subject matter which is examined under national grant procedures. Claim 10 has nonetheless been considered because the identified subject matter does not contravene Australian law.

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

no international search report has been established for said claim Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

the written form has not been furnished or does not comply with the standard.  
 the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims 9	YES
	Claims 1-8, 10, 11	NO
Inventive step (IS)	Claims -	YES
	Claims 1-11	NO
Industrial applicability (IA)	Claims 1-11	YES
	Claims -	NO

**2. Citations and explanations (Rule 70.7)**

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1: EP 028525 A  
D2: US 5866152 A  
D3: US 5559092 A  
D4: US 4126674 A  
D5: AU 50181/90 A  
D6: AU 42690/97 A  
D7: Remington

Novelty (N) Claims 1-11

D7 (Remington) is cited as an example of common general knowledge of the art of cosmetics and pharmaceutical formulation chemistry. D1 discloses cosmetic and pharmaceutical compositions as claimed in claims 1-8, 10, and 11. D2, D3 and D5 disclose cosmetic and pharmaceutical compositions as claimed in claims 1, 4-8, 10 and 11. D4 discloses cosmetic and pharmaceutical compositions as claimed in claims 1, 2, 4, 7-8, 10 and 11. In light of comments made in Box VIII, D6 discloses claims 1-11.

The invention as claimed in claims 1-11 resides in the use of known cosmetic and pharmaceutical bulking/dispersing/solvents/thickening excipients such as PEG, hydroxypropylcellulose and PPG. The use of such agents in substantially non-aqueous compositions is known (for example, see Remington). The variation of concentration of these agents in order to obtain degrees of viscosity is also well known to the skilled addressee (a formulation chemist) as would the selection of a well known excipient in order not to adversely effect the detergent and/or pharmaceutical active. Thus the choice of bulking/dispersing/thickening excipient and its concentration does not confer novelty on these claims.

None of the cited documents disclose the composition of claim 9.

(Continued in Supplemental Box)

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The use of the term "detergent" within the claim includes compounds such as surfactants (also used as stabilisers). It also includes the use of perfume, ethanol etc. as all these compounds are detergents (cleaning agents).

The bulking agent can also have other activities, for example, glycerol and PEG.

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

C ntinuation f B x V

Inventive Step (IS) Claims 1-11

In light of comments made above, the person skilled in the art, with the same problem to be solved and in light of the given documents, alone or in combination and the common general knowledge of formulation chemistry, would be led to investigate the invention as presently claimed. The compounds of claim 9 are known pharmaceuticals only slightly soluble in water.

Industrial Applicability Claims 1-11

Claims 1-11 are considered to be industrial applicable.

**PATENT COOPERATION TREATY  
PCT  
INTERNATIONAL PRELIMINARY EXAMINATION**

REC'D 08 JUN 2001
REPORT
PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference  P17237PC00	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International Application No.  PCT/AU00/00389	International Filing Date ( <i>day/month/year</i> )  1 May 2000	Priority Date ( <i>day/month/year</i> )  29 April 1999	
International Patent Classification (IPC) or national classification and IPC  Int. Cl. <sup>7</sup> A61K 47/44    A61P 17/04, 17/06, 17/14			
<b>Applicant</b> SOLTEC RESEARCH PTY. LTD. et al			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheet(s).

3. This report contains indications relating to the following items:

I	<input checked="" type="checkbox"/> Basis of the report
II	<input type="checkbox"/> Priority
III	<input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/> Lack of unity of invention
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input type="checkbox"/> Certain documents cited
VII	<input type="checkbox"/> Certain defects in the international application
VIII	<input checked="" type="checkbox"/> Certain observations on the international application

Date of submission of the demand  16 November 2000	Date of completion of the report  16 May 2001
Name and mailing address of the IPEA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  <b>JENNIFER FERNANCE</b> Telephone No. (02) 6283 2416

**I. Basis of the report****1. With regard to the elements of the international application:\***

the international application as originally filed.

the description,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on with the letter of

the claims,      pages , as originally filed,  
                              pages , as amended (together with any statement) under Article 19,  
                              pages , filed with the demand,  
                              pages , received on with the letter of

the drawings,      pages , as originally filed,  
                              pages , filed with the demand,  
                              pages , received on with the letter of

the sequence listing part of the description:  
                              pages , as originally filed  
                              pages , filed with the demand  
                              pages , received on with the letter of

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:**

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

**4.  The amendments have resulted in the cancellation of:**

the description,      pages

the claims,           Nos.

the drawings,          sheets/fig.

**5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be nonobvious), or to be industrially applicable have not been examined in respect of:

the entire international application,  
 claims Nos:

because:

the said international application, or the said claims No. 10 relates to the following subject matter which does not require an international preliminary examination (*specify*):

Rule 67 lists the subject matter which under Article 34(4)(a)(i) an international preliminary examination is not required to be carried out. At item (iv) it specifies methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods, as such matter. However the agreement between WIPO and Australia further qualifies this by excepting from exclusion any subject matter which is examined under national grant procedures. Claim 10 has nonetheless been considered because the identified subject matter does not contravene Australian law.

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.  
 no international search report has been established for said claim Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

the written form has not been furnished or does not comply with the standard.  
 the computer readable form has not been furnished or does not comply with the standard.

V.	<b>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</b>		
1.	Statement		
	Novelty (N)	Claims 9	YES
		Claims 1-8, 10, 11	NO
	Inventive step (IS)	Claims -	YES
		Claims 1-11	NO
	Industrial applicability (IA)	Claims 1-11	YES
		Claims -	NO

## 2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1: EP 028525 A  
 D2: US 5866152 A  
 D3: US 5559092 A  
 D4: US 4126674 A  
 D5: AU 50181/90 A  
 D6: AU 42690/97 A  
 D7: Remington

Novelty (N) Claims 1-11

D7 (Remington) is cited as an example of common general knowledge of the art of cosmetics and pharmaceutical formulation chemistry. D1 discloses cosmetic and pharmaceutical compositions as claimed in claims 1-8, 10, and 11. D2, D3 and D5 disclose cosmetic and pharmaceutical compositions as claimed in claims 1, 4-8, 10 and 11. D4 discloses cosmetic and pharmaceutical compositions as claimed in claims 1, 2, 4, 7-8, 10 and 11. In light of comments made in Box VIII, D6 discloses claims 1-11.

The invention as claimed in claims 1-11 resides in the use of known cosmetic and pharmaceutical bulking/dispersing/solvents/thickening excipients such as PEG, hydroxypropylcellulose and PPG. The use of such agents in substantially non-aqueous compositions is known (for example, see Remington). The variation of concentration of these agents in order to obtain degrees of viscosity is also well known to the skilled addressee (a formulation chemist) as would the selection of a well known excipient in order not to adversely effect the detergent and/or pharmaceutical active. Thus the choice of bulking/dispersing/thickening excipient and its concentration does not confer novelty on these claims.

None of the cited documents disclose the composition of claim 9.

(Continued in Supplemental Box)

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The use of the term "detergent" within the claim includes compounds such as surfactants (also used as stabilisers). It also includes the use of perfume, ethanol etc. as all these compounds are detergents (cleaning agents).

The bulking agent can also have other activities, for example, glycerol and PEG.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU00/00389

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

**Continuation of Box V**

Inventive Step (IS) Claims 1-11

In light of comments made above, the person skilled in the art, with the same problem to be solved and in light of the given documents, alone or in combination and the common general knowledge of formulation chemistry, would be led to investigate the invention as presently claimed. The compounds of claim 9 are known pharmaceuticals only slightly soluble in water.

Industrial Applicability Claims 1-11

Claims 1-11 are considered to be industrial applicable.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00389

**A. CLASSIFICATION OF SUBJECT MATTER**Int. Cl. <sup>7</sup>: A61K 47/44, A61P 17/06, 17/14, 17/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K WITH ELECTRONIC DATABASE SEARCH TERMS AS INDICATED BELOW.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
AU: IPC AS ABOVEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS/DERWENT/MEDLINE:

1) shampoo and [antifungal or fungal or dandruff or psoriasis or antipsoriasis or antibacterial]

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP-A-028525 (Orion-yhtymä Oy) 13 May 1981.	1-11
X	US A 5866152 (Takebayashi et al) 2 February 1999 -in particular col. 2 lines 8-36.	1-11
X	US A 5559092 (Gibson et al) 24 September 1996 -in particular col. 6 lines 3-60, col. 14 line 26-col. 18 line 19.	1-11

Further documents are listed in the continuation of Box C     See patent family annex

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	earlier application or patent but published on or after the international filing date
"E" earlier application or patent but published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  
21 June 2000Date of mailing of the international search report  
**05 JUL 2000**

Name and mailing address of the ISA/AU

Authorized officer

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaaustralia.gov.au  
Facsimile No. (02) 6285 3929**JENNIFER FERNANCE**  
Telephone No : (02) 6283 2416

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00389

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US A 4126674 (Mausner) 21 November 1978 -in particular col. 1 lines 29-49, col. 3 lines 3-18 and the examples.	1-11
X	AU-A-50181/90 (Procter & Gamble Co.) 8 August 1991 -in particular pages 3-8, 12-16	1-11
X	AU-A-42690/97 (Procter & Gamble Co.) 2 April 1998 -in particular pages 1 and 2.	1-11
Y	Remington: The Science and Practice of Pharmacy, 19 <sup>th</sup> Ed <sup>n</sup> , 1995, Mack Publishing Co. Pages 1395-1406	1-11

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/AU00/00389**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
EP	028525	AR	224783	AU	63515/80	DK	4536/80
		GR	68425	JP	56097212	NO	803246
		PL	227579	ZA	8006112		
US	5866152	BR	9605972	EP	782849	JP	10081616
		TR	970489				
US	5559092	AU	38704/93	BR	9302025	CA	2096507
		EP	571198	JP	6032726		
US	4126674	AR	218450	AU	25048/77	BR	7702988
		CA	1091585	DE	2721278	ES	458646
		FR	2350835	IT	1079004	JP	53004010
		MX	148705	ZA	7702805	CH	612089
		GB	1566339				
AU	50181/90	CA	2013761	CN	1053743	JP	3232812
		JP	4134018	NZ	232706	PH	27556
		US	5104645				
AU	42690/97	WO	9810742	EP	868170	CA	2237557
		CN	1207035	US	5993787		

**END OF ANNEX**